The real-world patient experience of fingolimod and dimethyl fumarate for multiple sclerosis

Publish Date:

Thursday, September 1, 2016

Category:

News Organization:

BMC Research Notes

Source URL:

Disease-modifying therapies in MS were for many years only available to patients as an infusion or an injection, which could be burdensome to patients who struggled with adherence and side effects. In the past few years a number of oral medications have been approved for the treatment of MS which allow patients to treat their condition with daily pills, however it remains unclear what the real-world experience of these treatments might be in comparison with results from controlled clinical trials. In a survey of 281 patients who had taken either fingolimod or dimethyl fumerate we used validated measures to probe their perceived efficacy, side effects, burden, and overall satisfaction to better understand the patient treatment journey.